Onward Therapeutics has raised NT$900 million, or approximately $28 million, in Series B financing to support its clinical-stage cancer programs, clinical-supply manufacturing, and early research.
The round was completed through two closings, with the second occurring in October 2026.
It represents Onward’s first capital increase since the company completed a share exchange and moved its global headquarters from Switzerland to Taiwan in October 2025.
Before that transaction, Onward had raised CHF 75.5 million, or approximately $90 million, through earlier rounds.
New And Existing Investors Support The Round
Existing shareholders participating in the Series B included CDIB Capital Healthcare Ventures and Hong Kong Chlitina International.
New institutional investors included Beiley Biofund, Everbright Biofund, Test Rite International, Grand Fortune Venture Capital, Hercules Bioventure Partners, MitoBitTech Venture, and Top Taiwan Venture Capital.
Individual investors also participated.
Onward plans to use the funding across a pipeline that includes two clinical-stage programs and two early-stage discovery projects.
Advancing Antibody And Cell Therapy Programs
OT-A201 is a tetravalent bispecific antibody designed to address multiple mechanisms of tumor immune evasion and resistance.
The program has completed monotherapy dose escalation in solid tumors and advanced into Phase 1b development. Planned work includes expansion cohorts in selected cancer types and combination regimens.
In blood cancers, Onward expects to complete enrollment in a Phase 1a study by the end of 2026.
The company has reported preliminary tumor responses and disease stabilization with what it described as a manageable safety profile. These are early clinical observations and require confirmation through additional trials.
OT-C001 is an off-the-shelf natural killer cell therapy derived from umbilical cord blood. It is being evaluated with rituximab in France for patients with diffuse large B-cell lymphoma who relapsed after or did not respond to CAR-T and T-cell engager treatments.
Early-stage programs include an oncology metabolism project and an antibody targeting tumor-associated antigens.
Onward is preparing to register on the Taipei Exchange’s Emerging Stock Board by the end of 2027. It also plans to expand its Taiwan team and begin local clinical trials.
KEY QUOTES:
This financing, our first since establishing our global headquarters in Taiwan, allows us to advance our clinical programs while building our R&D presence here. We are grateful for the continued support of our existing shareholders and welcome our new investors. Many patients with difficult-to-treat or relapsed cancers still have limited treatment options. We aim to bring them new options through different types of cancer therapies.
Dr. C. Grace Yeh, Chairperson and CEO of Onward Therapeutics
Our priority is to translate innovative science into meaningful clinical results. By focusing on indications where our therapies have the greatest potential to overcome treatment resistance, we aim to build a differentiated oncology pipeline to deliver new treatment options for patients.
Dr. Armand de Gramont, President of Research and Development at Onward Therapeutics

